fda bans tirzepatide compounded 🚨There's been a lot of confusion lately, so let's clear this FDA Shares Safety Data About

Continued use of the medication to promote maintenance of weight loss is recommended to help offset the reduction in energy expenditure and the increase in appetite that occurs with weight loss

2

Dosage form optimization: Controlled-release formulations enabling once-weekly oral administration Indication expansion: NASH, Alzheimers disease, cardiovascular protection Conclusion: A game-changing Molecule Design Orforglipron represents a triumph in small molecule drug designit demonstrates that clever chemical structure design can break through the dominance of biologics

Results vary depending on the individual and the treatment plan

The US Food and Drug Administration (FDA) has approved an additional indication for the weight loss drug semaglutidemarketed as Wegovy (Novo Nordisk) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity

Studies quantify midfacial volume loss at around 7-11% with typical weight reduction on these drugs